Go to content

News

Filters

Changing any of the form inputs will cause the content to refresh with the filtered results.

Skip filters

Next Generation LNP Technology for Infectious Disease Vaccines

Dr. Tom Chamberlain, Sr. Research Scientist I, Preclinical
World Vaccine Congress, Washington, D.C.

Read about Next Generation LNP Technology for Infectious Disease Vaccines

Lipid Nanoparticles (LNP) for mRNA Cancer Vaccine

Dr. Ghania Chikh, Sr. Director, Vaccine Development
World Vaccine Congress, Washington, D.C.

Read about Lipid Nanoparticles (LNP) for mRNA Cancer Vaccine

Optimizing Lipid Nanoparticles for Clinical Applications of mRNA Therapeutics 

Sean Semple, Vice President, Preclinical Research

BioChina International Convention, Suzhou, China

Read about Optimizing Lipid Nanoparticles for Clinical Applications of mRNA Therapeutics 

Next Generation LNP Technology for mRNA Vaccines

Tom Madden, Chief Executive Officer

Vaccine Innovation Forum, Shanghai, China

Read about Next Generation LNP Technology for mRNA Vaccines

Enhanced delivery and expression of mRNA to T-cells using CD8-targeted lipid nanoparticles with Athebody® Designed Ankyrin Repeat Proteins

Barbara Mui, Senior Research Scientist
Nucleic Acid Therapeutics and Targeted Delivery –  Keystone Symposia, Banff, AB, Canada

Read about Enhanced delivery and expression of mRNA to T-cells using CD8-targeted lipid nanoparticles with Athebody® Designed Ankyrin Repeat Proteins

mRNA-Lipid nanoparticle delivery systems for effective genetic and epigenetic editing medicines

Dr. Ying Tam, Chief Scientific Officer

Nucleic Acid Therapeutics and Targeted Delivery –  Keystone Symposia, Banff, AB, Canada

Read about mRNA-Lipid nanoparticle delivery systems for effective genetic and epigenetic editing medicines

Next Generation Lipid Nanoparticles for Clinical Development of mRNA-based Therapeutics

Dr. Ying Tam, Chief Scientific Officer

13th International mRNA Health Conference, Berlin, Germany

Read about Next Generation Lipid Nanoparticles for Clinical Development of mRNA-based Therapeutics

Effect of Body Weight and Anti-inflammatory Pre-medications and Concomitant Medications on the Pharmacodynamic Activity and Tolerability of mRNA-Lipid Nanoparticle Formulations in Monkeys 

Dr. Sherry Weppler, Sr. Research Scientist I
13th International mRNA Health Conference, Berlin, Germany

Read about Effect of Body Weight and Anti-inflammatory Pre-medications and Concomitant Medications on the Pharmacodynamic Activity and Tolerability of mRNA-Lipid Nanoparticle Formulations in Monkeys 

Novel Lipids with Improved Activity for Prophylactic Vaccine Development

Dr. Ghania Chikh, Sr. Director, Vaccine Development
10th International Conference on Vaccines Research & Development, Boston, MA
13th International mRNA Health Conference, Berlin, Germany

Read about Novel Lipids with Improved Activity for Prophylactic Vaccine Development

Development of mRNA-LNP for Cancer Vaccine

Dr. Fan Yan, Research Scientist II – 10th International Conference on Vaccines Research & Development, Boston, MA
Dr. Ghania Chikh, Sr. Director, Vaccine Development – 13th International mRNA Health Conference, Berlin, Germany

Read about Development of mRNA-LNP for Cancer Vaccine

An Alternative Method to RNA Lipid Nanoparticle Production

Mitchell Beattie, Research Scientist I
Controlled Release Society Annual Meeting & Exposition, Philadelphia, PA

Read about An Alternative Method to RNA Lipid Nanoparticle Production

Evolving Lipid Nanoparticles to Optimize Clinical Application of messenger RNA Therapeutics

Dr. Ying Tam, Chief Scientific Officer

TIDES USA, San Diego, CA

Read about Evolving Lipid Nanoparticles to Optimize Clinical Application of messenger RNA Therapeutics